Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | 5YP3L | — |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | UNK | — | — |
Interchangeability; This non-serious case was reported by a nurse via call center representative and described the occurrence of interchange of vaccine products in a 19-year-old female patient who received Men B NVS (Bexsero) (batch number 5YP3L, expiry date 31-JAN-2026) for prophylaxis. Co-suspect products included Meningococcal vaccine B rfHbpA/fHbpB (Trumenba) for prophylaxis. Previously administered products included Menactra (received 1st dose on 03-AUG-2016) and Menactra (received 2nd dose on 16-NOV-2021). On 12-FEB-2025, the patient received Bexsero. On 23-AUG-2022, the patient received Trumenba. On 12-FEB-2025, an unknown time after receiving Bexsero, the patient experienced interchange of vaccine products (Verbatim: Interchangeability). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-FEB-2025 The nurse reported that a patient received in the past 2 Menactra doses on August 3rd 2016 and November 16th 2021, and 1 dose of Trumenba on August 23rd 2022, and on February 12th 2025 they received a Bexsero vaccine, which led to interchange of vaccine products. Only Bexsero was given at their facility.